To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what steps the Government is taking to ensure that low-income countries have access to adequate supplies of the Oxford-AstraZeneca covid-19 vaccine.
12 January 2021
The UK is committed to rapid equitable access to safe and effective vaccines. The UK has committed up to £548 million to the COVAX Advance Market Commitment (AMC), an international initiative that will support global equitable access to vaccines, including the AstraZeneca/Oxford vaccine, in up to 92 low and middle-income countries. The AMC will supply 1 billion doses in 2021, vaccinating up to 500 million people.
COVAX has an advance purchase agreement with AstraZeneca for 170 million doses of the AstraZeneca/Oxford candidate at non-profit pricing. This is in addition to an existing agreement with the Serum Institute of India (SII) for 200 million doses - with options for up to 900 million doses more - of either the AstraZeneca/Oxford or Novavax vaccines (the latter is yet to complete phase 3 trials). The agreement with SII will see any combination of these vaccines be available at a price no greater than US$3 a dose.